Raya Therapeutic, Inc. Press Releases

• Published on June 3, 2025 - 06:00 GMT

  

  Raya Therapeutic Announces Two Posters at the ENCALS Meeting in Turin, Italy June 3-6

  Kim Staats, PhD., to present results of preclinical studies with RT1978 (Epertinib) and the combination of 2 NCEs with distinct mechanisms (RT1972 & RT1999). MONTREAL, QUEBEC, CANADA, June 3, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc. (“Raya …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on May 8, 2025 - 10:00 GMT

  

  Raya Therapeutic Appoints Juan Carlos Gomez MD, MBA, Chief Medical Officer of Shionogi and Company to its Board

  Dr. Gomez brings extensive neuroscience and orphan disease development experience to Raya as it plans multiple clinical trials in 2026. MONTREAL, QUEBEC, CANADA, May 8, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) a mission-driven company …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on March 3, 2025 - 18:00 GMT

  

  Raya Therapeutic Announces FDA and EMA Orphan Drug Designations for ALS with RT1978 (epertinib)

  The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS). MONTREAL, QUEBEC, CANADA, March 3, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) a mission-driven company …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on January 9, 2025 - 16:00 GMT

  

  Raya Therapeutic Announces 9 Orphan Drug Designations Across its 5 Clinical Stage Compounds

  The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS) & other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, January 9, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on December 5, 2024 - 15:00 GMT

  

  Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8

  Dr. Paul Lingor to present Phase 2 ROCK-ALS study. Raya also presenting promising new preclinical data of a combination of two new chemical entities (NCEs). MONTREAL, QUEBEC, CANADA, December 5, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on October 17, 2024 - 12:31 GMT

  

  Raya Therapeutic Announces Publication in The Lancet Neurology of ROCK-ALS Study Data for Fasudil in ALS

  Phase 2 trial showed Fasudil is safe and tolerable and provided evidence to support further investigation as a potential disease-modifying treatment for ALS. MONTREAL, QUEBEC, CANADA, October 17, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...